Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate cancer

E J Small1

  • 1University of California, San Francisco, Mount Zion Cancer Center 94115, USA.

Current Opinion in Oncology
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Prostate-specific antigen (PSA) screening aids early prostate cancer detection. Treatment strategies evolve, including androgen deprivation and novel therapies for advanced or refractory disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Urology
  • Oncology
  • Medical Diagnostics

Background:

  • Prostate cancer caused over 41,000 deaths in the US in 1996.
  • Prostate-specific antigen (PSA) screening detects clinically significant and organ-confined prostate cancers.
  • The free-to-total PSA ratio improves the positive predictive value of PSA screening.

Purpose of the Study:

  • To review current prostate cancer detection, risk assessment, and treatment strategies.
  • To discuss the role of androgen deprivation and emerging therapies.
  • To highlight areas of ongoing research and clinical debate.

Main Methods:

  • Review of current literature on prostate cancer screening and treatment.
  • Analysis of the impact of PSA screening and risk stratification tools (nomograms, Gleason score).

Related Experiment Videos

  • Evaluation of different therapeutic approaches including surgery, radiation, brachytherapy, and androgen deprivation therapy (ADT).

    • Main Results:

    • PSA screening enables early detection, necessitating advanced risk assessment tools.
    • Neoadjuvant ADT may reduce positive surgical margins; concurrent ADT may improve radiotherapy survival.
    • Modern brachytherapy shows comparable biochemical relapse-free rates to surgery and external beam radiation therapy for low-risk tumors.
    • Antiandrogen withdrawal is effective for progressive disease; nonhormonal agents show activity in hormone-refractory prostate cancer.

    Conclusions:

    • PSA screening has redefined advanced prostate cancer, prompting new treatment considerations.
    • The optimal management for positive margins or serologic progression requires further identification.
    • Ongoing trials, like the Prostate Cancer Intervention versus Observation Trial, are crucial for definitive treatment answers.
    • Various hormonal and nonhormonal agents offer therapeutic options for advanced and refractory prostate cancer.